SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer, PI3K, Alpelisib
Interventions: DRUG: Alpelisib|DRUG: Chemotherapy
Sponsor: UNICANCER